Is Vilin Bio Med overvalued or undervalued?

As of 17 September 2025, the valuation grade for Vilin Bio Med has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 34.94, while the EV to EBITDA ratio is also at 37.46, indicating a premium valuation compared to its peers. The PEG ratio of 0.93 suggests that the stock may not be adequately priced for its growth potential.
In comparison to its peers, Vilin Bio Med's valuation appears high; for instance, Sun Pharma has a PE of 33.91 and an EV to EBITDA of 22.95, while Cipla, rated as attractive, shows a PE of 23.36 and an EV to EBITDA of 16.45. Despite a strong one-year return of 33.6% compared to a slight decline in the Sensex, the current valuation metrics suggest that Vilin Bio Med is overvalued in the current market environment.